What type of study is this?

September 20, 2025Journal of the American Heart AssociationOpen Access

Population‐Based Study on the Coexistence of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Chronic Kidney Disease

View Full Paper

Ask AI

Bookmark

Authors

RGRachel Sze Jen GohNational University of Singapore JKJaycie KohNanyang Technological University MIMade Ayu Utami IntaranUniversity Health System

Discussion

Member takes

Implication

Population-based analysis finds coexisting metabolic dysfunction-associated steatotic liver disease and chronic kidney disease increases mortality risk.

Key Points

Individuals with both metabolic dysfunction-associated steatotic liver disease and chronic kidney disease have the highest mortality risk.
Among 14,818 participants, MASLD(+)/CKD(+) had a notable obesity rate of 77.6% and independent mortality risk (aHR 3.28).
Cox regression identified MASLD and CKD as independent predictors of mortality, with socioeconomic factors influencing disease prevalence.
The presence of advanced hepatic fibrosis exacerbates survival rates further in those with chronic kidney disease.

Cite This Study

Goh et al. (2025) studied this question.

synapsesocial.com/papers/68d46fc631b076d99fa69c73 https://doi.org/10.1161/jaha.125.041834

View Full Paper

Ask AI

Bookmark

Implication

Population-based analysis finds coexisting metabolic dysfunction-associated steatotic liver disease and chronic kidney disease increases mortality risk.

Population‐Based Study on the Coexistence of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Chronic Kidney Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Population‐Based Study on the Coexistence of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Chronic Kidney Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider